Pyrazoline compounds as mineralocorticoid receptorantagonists
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R1, R2, R3A, R3B, R4, R5, R6, R7, R8, and X are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods o...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | MAHONEY MATTHEW WILLIAM ARHANCET GRACIELA BARBIERI RICO JOSEPH GERACE |
| description | Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R1, R2, R3A, R3B, R4, R5, R6, R7, R8, and X are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, and intermediates are also disclosed. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AP2009004822A0</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AP2009004822A0</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AP2009004822A03</originalsourceid><addsrcrecordid>eNrjZLANqCxKrMrPycxLVUjOzy3IL81LKVZILFbIBYoUJebkJ-cXlWQm52emKBSlJqcWlOQXJeaVJKbn52UWlxTzMLCmJeYUp_JCaW4GZTfXEGcP3dSC_PjU4oLE5NS81JJ4xwAjAwNLAwMTCyMjRwNj4lQBAIdFMl0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Pyrazoline compounds as mineralocorticoid receptorantagonists</title><source>esp@cenet</source><creator>MAHONEY MATTHEW WILLIAM ; ARHANCET GRACIELA BARBIERI ; RICO JOSEPH GERACE</creator><creatorcontrib>MAHONEY MATTHEW WILLIAM ; ARHANCET GRACIELA BARBIERI ; RICO JOSEPH GERACE</creatorcontrib><description>Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R1, R2, R3A, R3B, R4, R5, R6, R7, R8, and X are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, and intermediates are also disclosed.</description><language>eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2009</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090430&DB=EPODOC&CC=AP&NR=2009004822A0$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76318</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090430&DB=EPODOC&CC=AP&NR=2009004822A0$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>MAHONEY MATTHEW WILLIAM</creatorcontrib><creatorcontrib>ARHANCET GRACIELA BARBIERI</creatorcontrib><creatorcontrib>RICO JOSEPH GERACE</creatorcontrib><title>Pyrazoline compounds as mineralocorticoid receptorantagonists</title><description>Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R1, R2, R3A, R3B, R4, R5, R6, R7, R8, and X are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, and intermediates are also disclosed.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2009</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLANqCxKrMrPycxLVUjOzy3IL81LKVZILFbIBYoUJebkJ-cXlWQm52emKBSlJqcWlOQXJeaVJKbn52UWlxTzMLCmJeYUp_JCaW4GZTfXEGcP3dSC_PjU4oLE5NS81JJ4xwAjAwNLAwMTCyMjRwNj4lQBAIdFMl0</recordid><startdate>20090430</startdate><enddate>20090430</enddate><creator>MAHONEY MATTHEW WILLIAM</creator><creator>ARHANCET GRACIELA BARBIERI</creator><creator>RICO JOSEPH GERACE</creator><scope>EVB</scope></search><sort><creationdate>20090430</creationdate><title>Pyrazoline compounds as mineralocorticoid receptorantagonists</title><author>MAHONEY MATTHEW WILLIAM ; ARHANCET GRACIELA BARBIERI ; RICO JOSEPH GERACE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AP2009004822A03</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2009</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>MAHONEY MATTHEW WILLIAM</creatorcontrib><creatorcontrib>ARHANCET GRACIELA BARBIERI</creatorcontrib><creatorcontrib>RICO JOSEPH GERACE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>MAHONEY MATTHEW WILLIAM</au><au>ARHANCET GRACIELA BARBIERI</au><au>RICO JOSEPH GERACE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Pyrazoline compounds as mineralocorticoid receptorantagonists</title><date>2009-04-30</date><risdate>2009</risdate><abstract>Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R1, R2, R3A, R3B, R4, R5, R6, R7, R8, and X are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, and intermediates are also disclosed.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_AP2009004822A0 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Pyrazoline compounds as mineralocorticoid receptorantagonists |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T23%3A06%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=MAHONEY%20MATTHEW%20WILLIAM&rft.date=2009-04-30&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAP2009004822A0%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |